Journal article icon

Journal article

Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial

Abstract:

Background and purpose Addition of carbogen and nicotinamide (hypoxia-modifying agents) to radiotherapy improves the survival of patients with high risk bladder cancer. The study investigated whether histopathological tumour features and putative hypoxia markers predicted benefit from hypoxia modification. Materials and methods Samples were available from 231 patients with high grade and invasive bladder carcinoma from the BCON phase III trial of radiotherapy (RT) alone or with carbogen and n...

Expand abstract

Actions


Access Document


Authors


Eustace, A More by this author
Agrawal, S More by this author
Expand authors...
Journal:
Radiotherapy and Oncology
Volume:
108
Issue:
1
Pages:
40-47
Publication date:
2013-07-05
DOI:
EISSN:
1879-0887
ISSN:
0167-8140
URN:
uuid:9603a0a0-8a14-4182-85a0-ece92e3bdb88
Source identifiers:
426149
Local pid:
pubs:426149

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP